GeneHealth - Your precision medicine

Zellweger Syndrome

Disease Details

Family Health Simplified

Buy Membership

Description: Zellweger syndrome is a rare genetic disorder characterized by the reduction or absence of functional peroxisomes in the cells, leading to severe neurological, liver, and kidney abnormalities.
Type: Zellweger syndrome is a peroxisomal biogenesis disorder (PBD) and is inherited in an autosomal recessive manner.
Signs And Symptoms: Zellweger syndrome is one of three peroxisome biogenesis disorders which belong to the Zellweger spectrum of peroxisome biogenesis disorders (PBD-ZSD). The other two disorders are neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD). Although all have a similar molecular basis for disease, Zellweger syndrome is the most severe of these three disorders.Zellweger syndrome is associated with impaired neuronal migration, neuronal positioning, and brain development. In addition, individuals with Zellweger syndrome can show a reduction in central nervous system (CNS) myelin (particularly cerebral), which is referred to as hypomyelination. Myelin is critical for normal CNS functions, and in this regard, serves to insulate nerve fibers in the brain. Patients can also show postdevelopmental sensorineuronal degeneration that leads to a progressive loss of hearing and vision.Zellweger syndrome can also affect the function of many other organ systems. Patients can show craniofacial abnormalities (such as a high forehead, hypoplastic supraorbital ridges, epicanthal folds, midface hypoplasia, and a large fontanel), hepatomegaly (enlarged liver), chondrodysplasia punctata (punctate calcification of the cartilage in specific regions of the body), eye abnormalities, and renal cysts. Newborns may present with profound hypotonia (low muscle tone), seizures, apnea, and an inability to eat.
Prognosis: Currently, no cure for Zellweger syndrome is known, nor is there a standard course of treatment. In November 2023, at five months old, Christopher Donald Miller was the first patient with Zellweger Syndrome in the United States to have a bone marrow transplant.Template:Https://fox8-com.translate.goog/news/akron-baby-battling-rare-condition-how-to-help/? x tr sl=en& x tr tl=pt& x tr hl=pt-BR& x tr pto=sc Infections should be guarded against to prevent such complications as pneumonia and respiratory distress. Other treatment is symptomatic and supportive. Patients usually do not survive beyond one year of age.
Onset: Zellweger syndrome typically presents at birth or in early infancy.
Prevalence: Zellweger syndrome is estimated to affect approximately 1 in 50,000 to 1 in 100,000 newborns.
Epidemiology: Zellweger syndrome is a rare, inherited autosomal recessive disorder. The prevalence is not precisely known but is estimated to be approximately 1 in 50,000 to 1 in 100,000 live births. It affects both males and females equally. The syndrome is part of a group of conditions known as peroxisome biogenesis disorders, which result from mutations in any of several PEX genes involved in the formation and function of peroxisomes in cells. Incidence and carrier rates can vary among different populations.
Intractability: Zellweger syndrome is generally considered intractable. It is a severe genetic disorder characterized by the reduction or absence of functional peroxisomes in the cells, leading to a range of developmental and metabolic issues. Currently, there is no cure, and treatment focuses on managing symptoms and supportive care.
Disease Severity: Zellweger syndrome is typically severe and often presents at birth or within the first few months of life. Most affected individuals do not survive past infancy or early childhood due to the severity of the symptoms and complications.
Healthcare Professionals: Disease Ontology ID - DOID:905
Pathophysiology: Zellweger syndrome is a peroxisomal biogenesis disorder resulting from mutations in any of the PEX genes responsible for peroxisomal assembly. The pathophysiology involves the failure to produce functional peroxisomes, which are cellular organelles essential for various metabolic pathways, including the beta-oxidation of very-long-chain fatty acids and the detoxification of hydrogen peroxide. The lack of functional peroxisomes leads to the accumulation of toxic substances, neurological abnormalities, liver dysfunction, and various developmental defects.
Carrier Status: Zellweger syndrome is an autosomal recessive disorder. This means that to have the disease, an individual must inherit two copies of the mutated gene, one from each parent. Carriers, who have only one copy of the mutated gene, typically do not show symptoms of the disease but can pass the gene to their offspring.
Mechanism: Zellweger syndrome is a genetic disorder caused by mutations in any of several PEX genes (most commonly PEX1). These genes are crucial for the normal function and biogenesis of peroxisomes, which are cellular organelles involved in various metabolic pathways. Without functional peroxisomes, cells cannot properly metabolize long-chain fatty acids and other essential lipids.

At the molecular level, the mutations lead to deficiencies in peroxisome function, including impaired import of peroxisomal matrix proteins and enzymes. This results in the accumulation of very long-chain fatty acids, phytanic acid, and bile acid intermediates, which cause damage to various tissues, including the liver, kidneys, and nervous system. The defective peroxisome function also affects plasmalogen synthesis, which is essential for normal brain and lung function. These molecular dysfunctions collectively contribute to the severe clinical manifestations of Zellweger syndrome, including developmental delays, hypotonia, seizures, and hepatomegaly.
Treatment: The nutrient malabsorption resulting from a lack of bile acids has resulted in elemental formula being suggested for feeding. They are low in fat, with less than 3 per cent of calories being derived from long-chain triglycerides (LCT). However, reducing dietary very long chain fatty acids (VLCFA) has not been shown to reduce blood VLCFA levels, likely because humans can endogenously produce most VLCFA. Plasma VLCFA levels are decreased when dietary VLCFA is reduced in conjunction with supplementation of Lorenzo's oil (a 4:1 mixture of glyceryl trioleate and glyceryl trierucate) in X-ALD patients. Since docosahexaenoic acid (DHA) synthesis is impaired [59], DHA supplementation was recommended, but a placebo-controlled study has since shown no clinical efficacy. Due to defective bile acid synthesis, fat-soluble supplements of vitamins A, D, E, and K are recommended.
Compassionate Use Treatment: Zellweger syndrome is a rare congenital disorder characterized by the reduction or absence of functional peroxisomes in the cells. It is part of a group of conditions known as peroxisomal biogenesis disorders. Currently, there is no cure for Zellweger syndrome, and treatment focuses on managing symptoms and supportive care.

Regarding compassionate use and experimental treatments:
1. **Compassionate Use:** This involves providing patients with access to investigational drugs outside of clinical trials, often on a case-by-case basis. Families and healthcare providers might explore compassionate use programs offered by pharmaceutical companies involved in relevant research.

2. **Off-Label Treatments:** While there are no specific off-label medications universally recommended for Zellweger syndrome, individual symptom management may involve off-label use of drugs targeting specific issues such as seizures, liver function, or nutritional support.

3. **Experimental Treatments:** Research is ongoing in gene therapy, enzyme replacement therapy, and small molecule treatments aimed at correcting the underlying genetic and biochemical defects. Participation in clinical trials for these experimental treatments may be an option for some patients.

Given the complexity and variability of Zellweger syndrome, discussions with a specialist in metabolic or genetic disorders are essential for exploring these potential treatment avenues.
Lifestyle Recommendations: Zellweger syndrome is a rare genetic disorder that affects various organs and systems due to peroxisome dysfunction. While there is no cure, certain lifestyle recommendations can help manage symptoms and improve quality of life. These include:

1. **Regular Medical Care:** Frequent monitoring by healthcare providers specializing in metabolic and genetic disorders.
2. **Nutrition:** A well-balanced diet tailored to individual needs, sometimes involving special nutritional formulas.
3. **Physical Therapy:** Gentle exercises to improve motor skills and prevent muscle atrophy.
4. **Occupational Therapy:** Assistance with daily activities to enhance independence.
5. **Sensory Stimulation:** Engaging activities to aid sensory integration and cognitive development.
6. **Hearing and Vision Support:** Use of hearing aids or glasses if necessary, along with regular check-ups.
7. **Seizure Management:** Administration of anti-epileptic medications as prescribed.
8. **Support Systems:** Joining support groups for emotional and social support for caregivers and families.

These measures aim to support overall well-being and manage the symptoms associated with Zellweger syndrome.
Medication: There is no specific medication for Zellweger syndrome. Treatment primarily focuses on managing symptoms and providing supportive care. This can include physical therapy, nutritional support, and interventions to address specific organ dysfunctions. Regular follow-up with a team of specialists is necessary for optimal management.
Repurposable Drugs: Research on repurposable drugs for Zellweger syndrome is limited due to its complex and rare nature. Some studies suggest potential benefits from drugs targeting associated symptoms or metabolic pathways:

1. **Cholic Acid and Chenodeoxycholic Acid**: These bile acids may help manage liver dysfunction and improve fat absorption.
2. **Antioxidants** (e.g., Vitamin E): To combat oxidative stress.
3. **Lorenzo's Oil**: May have limited efficacy in altering certain biochemical markers.

Clinical trials and further research are crucial to exploring these possibilities. Proper medical consultation and monitoring are essential for managing the condition.
Metabolites: In Zellweger syndrome, an accumulation of very long-chain fatty acids (VLCFAs) and other branched-chain fatty acids occurs due to the peroxisomal biogenesis disorder. These metabolite abnormalities are crucial for diagnosing and understanding the biochemical pathology of the disease. Other affected metabolites can include phytanic acid, pristanic acid, and plasmalogens.
Nutraceuticals: As of now, there are no specific nutraceuticals known to effectively treat Zellweger syndrome. Zellweger syndrome is a rare genetic disorder related to peroxisome biogenesis and currently lacks a cure or highly effective treatment. Management typically focuses on supportive care to address symptoms and improve quality of life. Always consult healthcare providers for personalized advice.
Peptides: Zellweger syndrome is not typically associated with specific peptide-based treatments or nanotechnology applications. It is a peroxisomal biogenesis disorder caused by mutations in genes responsible for peroxisome formation and function, leading to a range of developmental and metabolic issues. Management focuses on symptomatic and supportive care.